A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

Background: Targeting the vascular endothelial growth factor or the epidermal growth factor receptor (EGFR) has shown efficacy in advanced colorectal cancer (ACC), but no data are available on the combination of these strategies with chemotherapy in the first-line treatment. The CAIRO2 study evaluates the effect of adding cetuximab, a chimeric mAb against EGFR, to capecitabine, oxaliplatin and bevacizumab in the first-line treatment of ACC. Patients and methods: In all, 755 patients were randomly assigned between treatment with capecitabine, oxaliplatin and bevacizumab with or without cetuxima... Mehr ...

Verfasser: Tol, J.
Koopman, M.
Rodenburg, C. J.
Cats, A.
Creemers, G. J.
Schrama, J. G.
Erdkamp, F. L. G.
Vos, A. H.
Mol, L.
Antonini, N. F.
Punt, C. J. A.
Dokumenttyp: TEXT
Erscheinungsdatum: 2008
Verlag/Hrsg.: Oxford University Press
Schlagwörter: gastrointestinal tumors
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26631913
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://annonc.oxfordjournals.org/cgi/content/short/19/4/734